Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Generics
Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation
June 6th, 2009
On May 20, 2009, the US District Court for the District of New Jersey granted the request of AstraZeneca (NYSE:AZN) for an injunction barring Apotex (Apotex, Inc. and Apotex Corp.) from launching a generic version of AstraZeneca's PULMICORT RESPULES (budesonide inhalation suspension) in the US. No trial date for the patent litigation has been set. On March 30, 2009, the US Food and Drug Administration granted approval for a generic version of AstraZeneca's PULMICORT RESPULES to Apotex. AstraZeneca then filed suit following Apotex's indication of intent to market a generic version of AstraZeneca's PULMICORT RESPULES in the US prior to the expiration of AstraZeneca's...
Source: Law & Health Weekly (2009-06-06)
|
